Objective: Hyperuricemia has been associated with high blood pressure (BP) values, diabetes mellitus, metabolic syndrome and chronic kidney disease (CKD). In the present study, we assessed the gender-related relationships between serum uric acid (SUA) and cardionephrometabolic variables in central and east European hypertensive patients.

Methods: A total of 3206 treated hypertensive patients with available SUA levels from the BP-CARE study was analyzed. Correlations among SUA, BP values, BP control, diabetes mellitus, metabolic syndrome and CKD were performed according to gender.

Results: Twenty-five percent of the whole population showed hyperuricemia (28% in women and 23% in men). These patients were older and showed a greater burden of cardiovascular risk factors (high BP, BMI, glucose, total cholesterol and triglyceridemia). They also showed a greater prevalence of metabolic syndrome, diabetes mellitus, rate of uncontrolled BP, more than high cardiovascular risk and CKD. Prevalence of metabolic syndrome and uncontrolled BP was similar in normouricemic and hyperuricemic women, the latter displaying a higher prevalence of diabetes mellitus, high cardiovascular risk and CKD. Hyperuricemic men were characterized by a greater prevalence of metabolic syndrome, diabetes mellitus, high cardiovascular risk, rate of uncontrolled BP and CKD but not polytherapy. Logistic regression analysis showed that none of the evaluated variables, except CKD, displayed SUA as significant covariate.

Conclusion: Our findings provide evidence that a high prevalence of hyperuricemia occurs in hypertensive patients from central and east Europe. The data also show that gender-related differences in the association between SUA and cardionephrometabolic variables exist. This is also the case for the relationships between SUA and CKD.

Download full-text PDF

Source
http://dx.doi.org/10.1097/HJH.0000000000001908DOI Listing

Publication Analysis

Top Keywords

cardiovascular risk
20
diabetes mellitus
20
metabolic syndrome
20
hypertensive patients
12
central east
12
prevalence metabolic
12
high cardiovascular
12
gender-related differences
8
serum uric
8
uric acid
8

Similar Publications

Cardiovascular Outcomes in Patients with Complex Type 2 Diabetes Mellitus Treated with the Dual SGLT Inhibitor Sotagliflozin: A Meta-analysis.

Diabetes Ther

January 2025

The State Key Laboratory Management and Control for Complex Systems, Institute of Automation, Chinese Academy of Sciences, Beijing, 100190, People's Republic of China.

Introduction: Scientific publications have shown sodium-glucose co-transporter-2 (SGLT2) inhibitors to have several beneficial effects in patients with complex type 2 diabetes mellitus (T2DM). However, sodium-glucose co-transporter-1 (SGLT-1) inhibitor is still under investigation in clinical trials. Recently, a dual inhibitor of sodium-glucose co-transporter (SGLT1/2), sotagliflozin, has been approved for use in patients with T2DM.

View Article and Find Full Text PDF

Sodium zirconium cyclosilicate for MRAs optimization in HFrEF: lessons learned from the REALIZE-K trial.

Heart Fail Rev

January 2025

Centre d'Investigations Cliniques Plurithématique 1433 and INSERM U1116, CHRU Nancy, FCRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists), Institut Lorrain du Coeur Et Des Vaisseaux, CHRU de Nancy, Université de Lorraine, Nancy, France.

Mineralocorticoid receptor antagonists (MRAs) are a cornerstone of guideline-directed medical therapy for heart failure with reduced ejection fraction (HFrEF), offering significant benefits in reducing mortality and hospitalizations. However, their use is often constrained by the risk of hyperkalemia, particularly in patients with chronic kidney disease. Patiromer and sodium zirconium cyclosilicate (SZC), two novel potassium binders, have emerged as highly effective and safe tools for managing hyperkalemia and enabling the optimization of MRA therapy.

View Article and Find Full Text PDF

Mortality and diurnal temperature range in Virginia.

Int J Biometeorol

January 2025

Southeast Regional Climate Center, Department of Geography and Environment, University of North Carolina, Chapel Hill, NC, 27514, USA.

The relationship between diurnal temperature range (DTR) and daily mortality from 2005 to 2020 is examined for seven large metropolitan areas in Virginia using distributed lag non-linear models that control for temperature and humidity. The relative risk of mortality increases for very high DTR, and there is a short lag effect of several days. High risk DTR days are rare, typically occurring less than 1% of the time at most locations.

View Article and Find Full Text PDF

Management Strategies for Truncus Arteriosus: A Comparative Analysis of Staged vs. Primary Repair.

Pediatr Cardiol

January 2025

Department of Cardiovascular Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences and Okayama University Hospital, 2-5-1 Shikatacho, Kitaku, Okayama, Japan.

We reviewed the outcomes of truncus arteriosus repair (primary vs. staged repair incorporating bilateral pulmonary artery banding), focusing on survival, reintervention, and functional data. We analyzed 39 patients who underwent a first intervention for truncus arteriosus (staged, n = 19; primary, n = 20) between 1992 and 2022.

View Article and Find Full Text PDF

[Catheter ablation in patients with heart failure-who benefits?].

Herzschrittmacherther Elektrophysiol

January 2025

Klinik für Elektrophysiologie/Rhythmologie, Ruhr-Universität Bochum, Bochum, Deutschland.

Atrial fibrillation (AF) ablation is associated with a lower likelihood of death and surgical heart failure (HF) interventions in patients with HF. This effect is mainly driven by reduced all cause and cardiovascular death following ablation. Ablation also results in improved left ventricular (LV) function, decreased AF burden and AF regression.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!